NR

Nicotinamide Riboside (NR) is a form of vitamin B3 that converts to NAD+ via the salvage pathway. The patented form, Niagen (NR Chloride), is marketed by Niagen Bioscience (formerly ChromaDex) and is the form used in approximately 65 percent of all registered nicotinamide riboside clinical trials. NR is currently the only NAD+ precursor with both FDA New Dietary Ingredient notification and GRAS status in the US. Blood NAD+ rises 22 percent at 100 mg/day, 51 percent at 300 mg/day, and 142 percent at 1000 mg/day. Clinical endpoint benefits in cognition, muscle function, and disease populations are mixed and remain an active research question.

Discovery and Commercial History

NR was identified as a salvageable NAD+ precursor vitamin in 2004 by Charles Brenner, then at the University of Iowa, now at City of Hope and Chief Scientific Advisor at Niagen Bioscience. Brenner's group showed that NR has its own dedicated enzymatic pathway (NRK1 and NRK2 kinases) that converts it to NMN, which is then converted to NAD+ by NMNAT enzymes. This was the first identification of a third NAD+ precursor beyond nicotinamide (NAM) and nicotinic acid (NA), the two vitamins long known as forms of vitamin B3.

NR remained an academic curiosity until ChromaDex licensed the use of NR as a supplement and developed a patented crystalline form (NR Chloride) marketed as Niagen. ChromaDex spun off the consumer brand Tru Niagen for direct-to-consumer sales. In 2024 ChromaDex Corporation renamed its science division to Niagen Bioscience.

The U.S. Pharmacopeia has published an official dietary supplement monograph for NR Chloride, which is unusual for a novel supplement ingredient and reflects the depth of clinical and analytical work on the compound.

The Conze 2019 Dose-Response Trial

The foundational human pharmacokinetic and safety data comes from Conze, Brenner, and Kruger in Scientific Reports 2019. Design: 8-week randomized, double-blind, placebo-controlled trial in 140 overweight but otherwise healthy adults. Doses: placebo, 100 mg, 300 mg, or 1000 mg of Niagen daily.

Results:

• Whole blood NAD+ rose dose-dependently at 2 weeks: +22% at 100 mg, +51% at 300 mg, +142% at 1000 mg
• Increases were maintained throughout the 8 weeks
• No flushing at any dose (unlike niacin)
• No significant adverse events
• Other NAD+ metabolites (NAAD, NMN, NAM, MeNAM) also rose

This was the first study to demonstrate reliable, dose-dependent NAD+ elevation in healthy humans with a single oral precursor. It set the foundation for all subsequent NR trials in disease populations.

Disease-Population Trials

Parkinson's Disease (NADPARK, 2022): Brakedal et al., Cell Metabolism ran a Phase 1 trial of NR in newly diagnosed Parkinson's patients. NR was well-tolerated, raised brain NAD+ measured by MR spectroscopy, and produced exploratory signals of clinical benefit. A larger Phase 2 (NR-SAFE/NR-PD) followed.

Mild Cognitive Impairment (Orr 2024): Orr et al. in GeroScience ran a randomized placebo-controlled trial in older adults with mild cognitive impairment. NR significantly increased blood NAD+ as expected. NR was well-tolerated. NR did not alter cognition on the cognitive test battery. Cerebral blood flow was reduced by NR treatment, but the reduction did not survive multiple-comparisons correction. The authors concluded that a larger trial of longer duration would be needed to determine cognitive potential. This is an important negative result in the cognitive enhancement literature on NR.

Muscle Regeneration (Jensen 2022): Jensen et al. in JCI Insight randomized 32 elderly individuals (55-80 years) to NR + Pterostilbene (1000 mg NR + 200 mg PT) vs placebo for 45 days. The intervention was started 14 days before electrically induced muscle injury and continued for 30 days after. Muscle stem cell (MuSC) function and regeneration markers were tracked over 30 days. The trial showed modest signals but did not produce a clear winning effect of the combination on the primary functional endpoints.

Long COVID (2025): Reiten et al. in eClinicalMedicine reported a 24-week double-blind placebo-controlled trial in 58 community-dwelling participants with long-COVID. Dose: 2000 mg/day NR. Trial design used a placebo lead-in. Primary outcomes included NAD+ levels and cognitive/symptom recovery measures. Funded by Niagen Bioscience and the MGH McCance Center for Brain Health.

Hypertension (2025 pilot): A pilot RCT in 54 sedentary adults ≥55 years with daytime SBP ≥130 mmHg randomized to NR + exercise vs placebo + exercise vs NR alone for 6 weeks. The trial tested whether NR could enhance the blood-pressure-lowering effect of aerobic exercise. Pilot design, not powered for definitive efficacy.

Critical Context: NR vs NMN in 2026

The most commercially relevant fact about NR in 2026 is its regulatory advantage over NMN in the United States:

• NR: FDA NDI and GRAS status maintained, US Pharmacopeia monograph published, approved as supplement worldwide
• NMN: FDA reversed NMN to New Pharmaceutical Article (NPA) status on September 29, 2025, after a multi-year saga, removing it from the US dietary supplement market

This means that in the US in 2026, NR is the only oral NAD+ precursor that can be legally sold as a dietary supplement at the doses studied in clinical trials. NMN can no longer be marketed as a supplement in the US, though it remains available in other markets (Japan, China, several EU jurisdictions).

The mechanistic question of whether NR or NMN is superior at raising NAD+ remains contested in the literature. Both raise NAD+ reliably. Charles Brenner has argued that NMN must be dephosphorylated to NR before crossing the cell membrane (the Liu 2018 hypothesis), in which case NR is the cell-permeable precursor and NMN is a more expensive form. The Imai lab has identified SLC12A8 as a putative NMN transporter, supporting direct NMN uptake. The biochemistry is unresolved and the practical clinical difference, where measured, is modest.

Sarcopenia and Aging Meta-Analysis

A 2025 systematic review in the Journal of Cachexia, Sarcopenia and Muscle pooled NR and NMN trials for effects on skeletal muscle mass and function in older adults. The review concluded that evidence remains inconclusive: NAD+ rises reliably, but consistent effects on muscle mass, strength, or physical function endpoints in human older adults have not emerged from the controlled trial literature. This is a useful counterpoint to the marketing narrative around NAD+ precursors and aging.

NR is a form of vitamin B3 that enters the NAD+ salvage pathway as a substrate for the NR kinases NRK1 (NMRK1) and NRK2 (NMRK2). The conversion sequence:

NR → NMN → NAD+

Step 1: NR enters cells via specific transporters (the SLC52A nucleoside transporter family and equilibrative nucleoside transporters), then is phosphorylated by NRK1 (cytoplasmic, ubiquitous) or NRK2 (skeletal muscle, brain, kidney) to form NMN (nicotinamide mononucleotide).

Step 2: NMN is converted to NAD+ by the NMNAT family of enzymes (NMNAT1 in nucleus, NMNAT2 in cytoplasm and Golgi, NMNAT3 in mitochondria), each adding an AMP group to NMN to form NAD+.

The pathway is the same downstream of NMN for both NR and NMN supplementation. The upstream difference is that NR requires phosphorylation (an ATP-consuming step performed by NRK1/NRK2), while NMN is already phosphorylated.

The Cell-Membrane Question

A central biochemical controversy concerns how NMN crosses the plasma membrane:

• The classical view (favored by the Brenner lab) is that NMN cannot cross the cell membrane intact and must first be dephosphorylated to NR by extracellular ectonucleotidases (primarily CD73). In this model, NR is the cell-permeable precursor and NMN supplementation effectively works by reverting to NR before cell entry.
• An alternative view (Imai lab) identifies SLC12A8 as an NMN transporter in some tissues, supporting direct cellular NMN uptake.

In practice, both precursors raise intracellular NAD+ reliably, so the controversy may be more academic than therapeutic.

Downstream Effects of Increased NAD+

NAD+ is consumed by several enzyme classes whose activity is rate-limited by NAD+ availability:

• Sirtuins (SIRT1-7): NAD+-dependent deacetylases regulating metabolism, mitochondrial biogenesis, DNA repair, and circadian rhythm
• PARPs (poly-ADP-ribose polymerases): NAD+-consuming enzymes activated by DNA damage. Involved in DNA repair
• CD38: an ectoenzyme that consumes NAD+. Involved in calcium signaling and inflammation
• Mitochondrial Complex I: requires NAD+/NADH for electron transport chain function

NR-mediated NAD+ elevation has been documented to increase SIRT1 activity, enhance mitochondrial biogenesis markers, and reduce some inflammatory markers in human trials. The translation from biochemistry to clinical endpoint, however, has been less consistent than the upstream pharmacology would suggest.

Confirmed effects in controlled human trials:

• Reliable dose-dependent blood NAD+ elevation (22% to 142% across the studied dose range)
• Elevation of other NAD+ metabolites (NAAD, NMN, NAM, MeNAM)
• Reduction in some inflammatory cytokines in subset of trials (interleukin-6, soluble IL-2 receptor)
• No flushing (a major differentiator from nicotinic acid/niacin)
• Generally good tolerability

Disease-specific and physiological effects (controlled trials):

• Parkinson's: NADPARK Phase 1 showed brain NAD+ elevation and exploratory clinical signals
• Mild Cognitive Impairment: NAD+ rose, cognitive tests did not improve (Orr 2024)
• Muscle regeneration after induced injury (elderly): Mixed signals from NR + Pterostilbene combination (Jensen 2022)
• Hypertension: pilot data shows NR + exercise differs from exercise alone, magnitude TBD in larger trials
• Long COVID: 2025 trial data being analyzed

Effects in mouse and rat models (broader and more positive than human clinical trial data):

• Improved muscle stem cell function after injury
• Improved memory in some Alzheimer's models
• Reduced markers of mitochondrial dysfunction
• Improved insulin sensitivity in obese mice
• Modest lifespan extension in some studies (less consistent than dietary restriction)

Subjective user reports from supplement-use populations include improved energy, better sleep, and reduced post-exercise fatigue. These are uncontrolled and have not been replicated in the controlled trial literature.

Honest evidence framing: NR is one of the best-characterized NAD+ precursors in human trials, with consistent pharmacodynamics (NAD+ rises predictably) but inconsistent clinical endpoint benefit. The supplement industry narrative ("NR reverses aging") is not supported by the controlled human data, which is most accurately summarized as "NR raises NAD+ as expected. Whether NAD+ elevation produces meaningful clinical benefit in healthy or aging humans remains an active research question."

Doses used in clinical trials:

• 100 mg/day: pharmacokinetic studies, ~22% NAD+ elevation
• 300 mg/day: common consumer-supplement dose, ~51% NAD+ elevation
• 500 mg/day: NADPARK Parkinson's trial
• 1000 mg/day: most common "high-dose" research dose, ~142% NAD+ elevation, used in MCI, muscle regeneration, and hypertension trials
• 2000 mg/day: Long COVID 2025 trial
• 3000 mg/day: maximum dose tested in some trials, generally well tolerated

Manufacturer-recommended dosing:

• Tru Niagen 300 mg: foundational consumer dose
• Tru Niagen Pro 1000 mg: "clinical strength" consumer dose, originally physician-only

Timing: most trials use once-daily morning dosing. Some users split doses to twice daily. The pharmacokinetic data suggests once-daily is sufficient given the multi-hour intracellular NAD+ elevation pattern.

Cycling: most trials use continuous dosing. There is no controlled clinical evidence of benefit or harm from cycling versus continuous use. Some longevity-focused users cycle (e.g., 5 days on, 2 off, or 3 weeks on, 1 week off) based on speculative concerns about CD38 upregulation or feedback inhibition. This is not well supported by controlled data.

Co-supplementation: many consumer products combine NR with pterostilbene (Resveratrol analog), trigonelline (an emerging NAD+ precursor identified by Membrez 2024 Nature Metabolism), or apigenin (a CD38 inhibitor). Some of these combinations have controlled data (NR + PT muscle trial), others are speculative.

Bioavailability: oral NR has high bioavailability, particularly in the chloride salt form (Niagen). Niagen Bioscience reports NR Chloride is rapidly absorbed and elevates NAD+ within hours. The 2-week timeline to peak NAD+ elevation reflects gradual saturation of tissue NAD+ pools rather than absorption kinetics.

Special populations:

• Older adults: same dosing as younger adults
• Renal impairment: limited data, no specific dose adjustment recommended
• Hepatic impairment: limited data
• Pregnancy/breastfeeding: not studied, avoid
• Pediatric: not studied, avoid

Common adverse effects (≥5% incidence in trials):

• Mild gastrointestinal complaints (nausea, bloating, diarrhea), typically at higher doses (1000+ mg), at rates similar to placebo
• Mild fatigue or sleep changes in some users at initiation
• Headache, infrequent

No flushing: this is the principal pharmacological differentiator from nicotinic acid/niacin. NR does not activate the GPR109A receptor in skin that drives the niacin flush response.

Serious adverse effects: none clearly attributable to NR in the published trial literature.

Safety profile from rat toxicology:

• 90-day study NOAEL: 300 mg/kg/day
• 90-day study LOAEL: 1000 mg/kg/day
• Similar toxicity profile to nicotinamide at equimolar doses
• No genotoxicity in bacterial reverse mutagenesis, in vitro chromosome aberration, or in vivo micronucleus assays

Specific theoretical and noted concerns:

• CD38 upregulation: chronic NAD+ elevation has been suggested to upregulate CD38, the major NAD+-consuming enzyme of inflammaging. Whether this matters clinically is unresolved.
• Cerebral blood flow: the 2024 Orr MCI trial detected reduced cerebral blood flow with NR treatment that did not survive multiple-comparisons correction. This finding warrants monitoring in longer trials.
• Cancer pathway considerations: NAD+ supports many proliferative pathways. The relationship between NR supplementation and cancer is not well characterized. Most longevity-targeted compounds (including rapamycin and metformin) face this same theoretical question and the practical answer requires long-duration epidemiology that does not yet exist for NR.
• Drug interactions: NR is unlikely to have major pharmacokinetic interactions because it does not significantly modulate major CYP450 enzymes at typical doses. PARP inhibitor interaction (theoretical, as both modulate NAD+ pools) has not been characterized.

Pregnancy and pediatrics: avoid due to lack of safety data, not because of any specific reported concern.

Methylation buffer: methyl donors (B12, folate, betaine, TMG) are sometimes recommended alongside NR/NMN because both NR and NMN catabolism through NAM eventually produces methyl-nicotinamide via NNMT, consuming SAM (S-adenosylmethionine). The clinical relevance of methylation depletion at standard NR doses (100-1000 mg/day) is debated. The concern is more theoretical at typical doses than at the very high doses (≥2 g/day) used in some research protocols.

NR sits at the center of the NAD+ precursor commercial market. The closest comparators:

• NMN: the alternative NAD+ precursor. Both raise NAD+ reliably. Major regulatory divergence in 2026: NR retains NDI/GRAS status, while NMN was reversed to NPA in September 2025 and removed from US supplement market. Mechanistically the two converge after the first salvage step.
• NAD+: the direct molecule. Available as IV infusion (compounded), nasal spray, and oral (poor bioavailability). IV NAD+ raises NAD+ acutely but expensively and impractically for daily maintenance. Oral NR is the practical alternative for sustained elevation.
• Nicotinamide (NAM): classical vitamin B3, raises NAD+ but at high doses inhibits sirtuins (the very enzymes NAD+ elevation is meant to activate). Generally not recommended as a longevity-focused precursor.
• Nicotinic Acid (NA, niacin): lipid-modifying vitamin B3 form. Raises NAD+ but causes intense flushing. Used in cardiovascular medicine, not in longevity supplementation.
• Trigonelline: an emerging NAD+ precursor identified by Membrez 2024 in Nature Metabolism. Found in coffee. Improves muscle function during aging in preclinical studies. Reduced in human sarcopenia. Not yet in widespread consumer products but on the trajectory to enter the market.

Common consumer stacks:

• NR + Pterostilbene: the Basis formulation (Elysium Health) and Tru Niagen + PT combinations. Pterostilbene is a resveratrol analog with higher bioavailability, marketed as a sirtuin activator. Jensen 2022 muscle trial showed mixed effects of the combination.
• NR + Apigenin: apigenin inhibits CD38, theoretically extending the half-life of newly synthesized NAD+. Combination is supplement-industry-favored, with thin clinical evidence.
• NR + Quercetin/Fisetin: senolytic combinations. Speculative additivity.
• NR + TMG (trimethylglycine, betaine): methylation buffer. Common pairing, particularly at higher NR doses (≥1000 mg/day).
• NR + Methylated B-vitamins: similar rationale to TMG, addressing methylation demand of NAM disposal.
• NR + Coenzyme Q10: mitochondrial complementarity. No controlled trial data, plausible mechanism.

Combinations to use with caution:

• PARP inhibitors (olaparib, etc., used in oncology): theoretical interaction via shared NAD+ pool. Discuss with oncology team.
• Active cancer treatment: see PARP inhibitor note. NAD+ elevation is not contraindicated but warrants oncologist consultation.
• Very high-dose NAM: nicotinamide at high doses inhibits sirtuins, partially offsetting the NR effect. Avoid stacking with nicotinamide >500 mg/day.

Combinations to avoid:

• Other NAD+ precursors stacked: there is no benefit to combining NR with NMN or with high-dose NAM. The pathway converges at NAD+ and additional substrate beyond saturation produces diminishing returns.
• Pregnancy and breastfeeding: avoid due to lack of safety data.

The most actionable framing of NR in 2026: this is the only US-legal oral NAD+ precursor supplement with full regulatory and clinical-trial backing. It reliably raises blood NAD+. The translation of NAD+ elevation to clinical endpoints in healthy aging humans is the active research question and the answer so far is mixed. NR has the most replicated pharmacodynamic profile of any longevity-targeted supplement. Whether that translates to lifespan or healthspan extension is genuinely unknown.

For informational and educational purposes only. Not medical advice. Not for human consumption unless prescribed by a licensed physician for an FDA-approved indication. Consult a qualified healthcare provider before using any peptide or pharmaceutical product.